[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593690":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":32,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CIPN",null,"Individuals with chemotherapy-induced peripheral neuropathy with a confirmed diagnosis using the nerve conduction study",[13],"Other: No intervention (observational study)",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy","Healthy adults with no known health conditions affecting their mobility, balance, or lower extremity muscle strength",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"No intervention (observational study)","No intervention; observational study",[9,15],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Hongwu Wang, PhD","CONTACT","+1 (352) 273-9934","hongwu.wang@phhp.ufl.edu",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":31},"Raghuveer Chandrashekhar, MS","rchandrashekhar@ufl.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Gainesville","Florida","32611","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-82.32483,29.65163,{"lat":44,"lon":43},[47,49],{"name":25,"role":26,"phone":48,"phoneExt":10,"email":28},"352-273-9934",{"name":25,"role":50,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100593690","relationship-between-great-toe-strength-and-symptoms-of-chemotherapy-induced-peripheral-neuropathy-cipn-100593690",false,"NCT07009717","Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)","The Role Of Great Toe Strength And Its Association With The Severity Of Symptoms Of Chemotherapy-Induced Peripheral Neuropathy (CIPN)","Eligibility Criteria for Chemotherapy-Induced Peripheral Neuropathy (CIPN) group:\n\nInclusion Criteria:\n\n* At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe\n* Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported)\n* Within 3 - 6 months of starting chemotherapy and a confirmed diagnosis of CIPN using the current clinical reference standard of Nerve conduction study.\n\nExclusion Criteria:\n\n* Comorbidities including but not limited to diabetes, arthritis, hypertension, thyroid disease, and heart disease, . that have been reported to be associated with the incidence of peripheral neuropathy and\u002For progression of CIPN.\n* Toe deformities or impairments not caused by CIPN (including but not limited to hallux valgus\u002Fvarus, hallux limitus, hallux rigidus, hammer toe deformity, claw toe, bunions, webbed toes)\n* Self-reported impairment or impact on the strength of the foot, ankle, and\u002For great toe due to past medical or surgical history.\n\nEligibility Criteria for Healthy Control group: The participants recruited for this group will be age- and sex- matched to the CIPN group\n\n* Inclusion Criteria:\n* At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe\n* Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported)\n* No known health conditions that have been reported to be associated with different impairements in mobility, balance, and muscle strength (particularly in the lower extremity)",true,"ALL","18 Years","90 Years",{"count":65,"type":66},30,"ESTIMATED","OBSERVATIONAL","Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to evaluate GTS in individuals with CIPN and healthy adults using ToeScale and see how it relates to nerve issues from chemotherapy. Additionally, we aim to assess the usability of the novel GTS assessment device, ToeScale among the participants. As a part of this study visit, you will complete some questionnaires followed by GTS and balance and gait assessments.",[70,15],"Chemotherapy-induced Peripheral Neuropathy (CIPN)",[72,73,74,75,76],"Great Toe strength","chemotherapy-induced peripheral neuropathy","muscle weakness","clinical biomarker","force development curve","2026-02-09",{"date":79,"type":80},"2026-02-10","ACTUAL",{"date":82,"type":80},"2025-08-05",{"date":84,"type":66},"2026-12-31",{"name":5,"class":6},1]